Kura Oncology to Participate in Three Upcoming Investor Conferences

Core Insights - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment [2] - The company has an investigational therapy, ziftomenib, which has received Breakthrough Therapy Designation from the FDA for relapsed/refractory NPM1-mutant acute myeloid leukemia [2] - Kura Oncology has entered a global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib for AML and other hematologic malignancies [2] Company Pipeline - Ziftomenib is the first and only menin inhibitor to receive Breakthrough Therapy Designation for R/R NPM1-mutant AML [2] - Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed [2] - KO-2806, a next-generation farnesyl transferase inhibitor, is currently in a Phase 1 dose-escalation trial [2] - Tipifarnib is in a Phase 1/2 trial in combination with alpelisib for PIK3CA-dependent head and neck squamous cell carcinoma [2] Upcoming Events - Troy Wilson, CEO, will participate in three investor conferences in March 2025 [3] - The events include the TD Cowen Health Care Conference, Barclays Global Healthcare Conference, and Leerink Partners Global Biopharma Conference [3] - Live audio webcasts will be available on Kura's website, with archived replays following the events [1][3]